|
|
 |
|
Viewing report
|
|
|
|
Pricing and Reimbursement: Innovative Risk-Sharing Strategies
Datamonitor, July 2009, Pages: 53
Novel niche biologics entering the market require high price points in order to provide manufacturers with a return on investment. However, with heightening regulatory scrutiny and increasing cost-pressures, a balance must be struck between incentivizing Pharma to develop novel drugs with high unmet needs, and that of the healthcare payers which fund healthcare costs.
Scope
- Overview of the different types of risk-sharing agreements adopted by manufacturers
- Insight into the utilization of such schemes in the UK, US, Italy and Australia
- Examination of the pros and cons of risk-sharing agreements
- Identification of key strategic recommendations for optimizing risk-sharing strategies
Highlights of this title
Risk-sharing schemes are ideal if a well-established biomarker can be used to unambiguously determine if a patient has responded to treatment, however for many other oncology drugs relevant biomarkers still need to be discovered hence impeding a more widespread adoption of these schemes.
The new NICE end-of-life guidance rule can be useful for drugs struggling to gain a positive NICE opinion. By targeting terminal patients with months to live, they can achieve market access and a route into the treatment of other stages of a disease, but only if further concessions are made to reduce the drugs QALY.
If a Health Technology Assessment (HTA) is introduced in the US, it could create a more cost-effective use of current US healthcare resources, however it is important to note this will increase the burden on Pharma to produce data, and could also effectively lead to the end of free pricing in the US.
Key reasons to purchase this title
- Understand the importance of cost-effectiveness and its impact on pricing and reimbursement of pharmaceuticals
- Gain insight into risk-sharing schemes and identify how these can be implemented and optimized
- Case study analysis of recent risk-sharing agreements in US, UK, Italy, and Australia
Customers who bought this item also bought
Lafferty Cards and Consumer Finance in the United Kingdom 2009
Insurance Industry in the United Kingdom - Global Strategic Business Report
Understanding the UK Car Insurance System Series
Payment Report United Kingdom
Mobile Metrics: Consumer Approaches to Mobile Telephone Insurance in the UK
The UK Insurance Market Outlook to 2015
Commercial Cards in the UK (Databook)
Bancassurance in the UK: Life, Non-Life and Creditor Insurance
Professional Indemnity Insurance in UK
Extended Warranties and Insurance for Mobile and Non-Mobile Consumer Products in the UK
|
|
|
|
